missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. Novus Biologicals™ Activin RIIB Antibody (bimagrumab), Novus Biologicals™
  7. 30044433

Novus Biologicals™ Activin RIIB Antibody (bimagrumab), Novus Biologicals™

Human Monoclonal Antibody

Brand:  Novus Biologicals™ NBP3-28282-1mg

 View more versions of this product

Product Code. 30044433

  • 920.00€ / 1mg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

Activin RIIB Monoclonal antibody specifically detects Activin RIIB in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Activin RIIB
Monoclonal
Unconjugated
Q13705
Human
Protein A purified
RUO
Primary
Reconstitute with sterile, distilled water to a final concentration of 1 mg/mL. Gently shake to solubilize completely. Do not vortex.
Store at -20°C in powder form. Store at -80°C once reconstituted.
IgG1
Flow Cytometry, ELISA, Functional Assay
bimagrumab
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
activin A receptor, type IIB, Activin receptor type IIB, activin receptor type-2B, ActR-IIB, ACTRIIB, EC 2.7.11, EC 2.7.11.30, MGC116908
ACVR2B
1 mg
Protein Kinase
93
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.